Efficacy of HMG-CoA reductase inhibitors in treating osteoporosis.
The Therapy Consultation section provides brief advice, in question-and-answer format, on how to handle specific drug-therapy problems. Readers are invited to submit questions, which will be referred to a consultant for an answer. The problems should not be highly specialized or unusual, nor should they be mundane. Questions are answered briefly, largely on the basis of judgment and personal experience of the consultant, although selected references may be cited to substantiate the consultant's advice.
Richard
April A
AA
Gaston Memorial Hospital, Gastonia, NC, USA.
Harrison
Tina M
TM
D000368:Aged; D015519:Bone Density / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors